The 19 references without contexts in paper O. Pylaeva A., K. Mukhin Yu., M. Mironov B., О. Пылаева А., К. Мухин Ю., М. Миронов Б. (2015) “Эффективность и переносимость препарата лакосамид (Вимпат) в лечении эпилепсии у взрослых (обзор литературы) // EFFICACY AND TOLERABILITY OF LACOSAMIDE (VIMPAT) FOR TREATMENT OF EPILEPSY IN ADULTS (A REVIEW)” / spz:neicon:rjdn:y:2014:i:4:p:59-68

1
Lacosamide as treatment of epileptic seizures – cost utility results for Sweden. Acta Neurol Scand 2010;121(6):406–12. 17. Borghs S., de la Loge C., Cramer J.A. Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled laco
(check this in PDF content)
2
Eur J Drug Metab Pharmacokinet 2012;37(4):241–8. 19. Chatzistefanidis D., Karvouni E.,
(check this in PDF content)
3
Kyritsis A.P., Markoula S. First case of lacosamide-induced psychosis. Clin Neuropharmacol 2013;36(1):27–8. 20. Chinnasami S., Rathore C., Duncan J.S. Sinu
(check this in PDF content)
4
Sperling M.R. et аl. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010;24(12):1041–54. 22. Chung S., Sperling M.R., Biton V. et al.
(check this in PDF content)
5
Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006;50(8):1016–29. 25. Errington A.C., Stöhr T., Heers C.,
(check this in PDF content)
6
Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73(1): 157–69. 26. Flores L.,
(check this in PDF content)
7
Bourgeois B. et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seiz
(check this in PDF content)
8
Gooty V.D. et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011;44(6):414–9. 31. Halasz P., Kalvi
(check this in PDF content)
9
Mazurkiewicz-Beldzinska M. et al.; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443
(check this in PDF content)
10
Serrano E. Initial post marketing experience with lacosamide in adult patients with epilepsy. Epilepsy Res 2012;98(2–3):260–3. 34. Harris J.A., Murphy J.A. Lacosamide: an adjunctive agent for
(check this in PDF content)
11
Management of focal-onset seizures. an update on drug treatment. Drugs 2006;66(13): 1701–25. 40. Jones G.L., Popli G.S., Silvia M.T. Lacosamide-induced valproic acid toxicity. Pediatr Neurol 2013;48(4):308–10.
(check this in PDF content)
12
Cook M.J. Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre. Acta Neurol Scand 2013;127(3):149–53. 42. Kelemen A., Halasz P. Lacosam
(check this in PDF content)
13
Mameniskiene R. et al.; SP757 Study Group. Intravenous lacosamide as short-term replacement for oral lacosamide in partialonset seizures. Epilepsia 2010;51(6):951–7. 48. Krauss G.L., Edwards H.B., Lin B
(check this in PDF content)
14
Efficacy of intravenous lacosamide as an addon treatment in refractory status epilepticus: a multicentric prospective study. Seizure 2013;22(1):77–9. 53.
(check this in PDF content)
15
Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother 2012;13(5):699–715. 58. Potschka H. Animal and human data: where a
(check this in PDF content)
16
Calderon R. et al. Lacosamide for epileptic seizures in patients with co-morbidities and unusual presentations of epilepsy. CNS Drugs 2011;25 Suppl 1:17–26. 61. Simoens S. Budget impact analysis of a
(check this in PDF content)
17
Lacosamide in patients with pharmacoresistant epilepsy. Expert Opin Pharmacother 2012;13(14):2065–72. 66. Verrotti A., Loiacono G., Pizzolorusso A. et al. Lacosamide in pediatric and ad
(check this in PDF content)
18
Lopez-Trigo J. et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav 2012;23(3):298–304. 68. Vishwanath
(check this in PDF content)
19
Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization. Neuroscience 2012;210:451–66. RGDN_04_2014 Block.indd 68RGD
(check this in PDF content)